Bluttropfen kann Leben retten: Babyscreening auf Krankheiten

18. Dezember 2024, 6:00 Uhr Lesezeit: 4 Min. Ein Bluttropfen vom Fuß eines Babys genügt, um viele Krankheit zu erkennen. (Archivbild) (Foto: picture alliance / Stefan Sauer/dpa-Zentralbild/dpa) Mit einem Genomischen Neugeborenen-Screening könnten Babys auf Hunderte Krankheiten getestet werden. Forscher in Heidelberg und Mannheim arbeiten an einem flächendeckenden Konzept. Direkt aus dem dpa-Newskanal: Dieser Text wurde automatisch von der Deutschen Presse-Agentur (dpa) übernommen und von der SZ-Redaktion

Read the full article here

Source: www.sueddeutsche.de

Categories: Oncologists1, General Medicine News

Tags: NEW_LIVES

Tweets with this article

Eva Winkler

"Bluttropfen kann Leben retten: Babyscreening auf Krankheiten" #NEW_LIVES @SZ @cpschaaf https://t.co/9ueqoeuSYW

Novel HER2 TKI Shows Preliminary Activity in Breast Cancer Brain Metastases

Phase 1 data may support further development of ZN-1041 combination therapies for a larger breast cancer population.

Cancer Network January 9, 2025

Addressing Unmet Needs in Synovial Sarcoma and Recent FDA Approval of Afami-cel

Panelists discuss how the major unmet needs in treating synovial sarcoma include developing targeted therapies that effectively address the SS18::SSX fusion oncogene, improving early detection…

OncLive.com January 9, 2025

Addition of an immune checkpoint inhibitor reduces the risk of disease progression for select patients with anal cancer

Click on the article title to read more.

ACS Journal Cancer January 9, 2025

Clinical Practice Insights Reveal the Complexity of Lymphoma Subtypes and Advances in First-Line Treatments: With Chandler Park, MD; and Joshua Brody, MD

Chandler Park, MD and Joshua Brody, MD discusses treatment challenges posed by the diverse spectrum of lymphomas, ranging from indolent subtypes, to aggressive diseases like…

OncLive.com January 9, 2025

CDC awards $2.3M research grant for young patients with breast cancer

The CDC has awarded Weill Cornell Medicine a 5-year, $2.3 million grant to advance equitable access to care for young patients with breast cancer. The…

HemOnc Today January 9, 2025

First-Line Belzutifan/Cabozantinib Delivers Responses and Manageable Toxicities in ccRCC

Frontline belzutifan plus cabozantinib elicited durable responses and was tolerable in patients with treatment-naive advanced ccRCC.

OncLive.com January 9, 2025

Market trouble threatens Labour’s economic plans

Chancellor Rachel Reeves may have to choose between tax rises and spending cuts, writes Henry Zeffman.

Clive Peedell January 9, 2025

New Ancestry-adjusted Lung Cancer Prediction Model

A new ancestry-adjusted risk prediction model, Genomic-informed Care for Motivating High Risk Individuals Eligible for Evidence-based Prevention (GREAT), may aid patients in decision-making around lung…

National Cancer Institute January 9, 2025

Tricking cells into trashing cancer

In a study published today in the Journal of Clinical Investigation, Fred Hutch Cancer Center cancer chemical biologist Behnam Nabet and his collaborators describe how…

Fred Hutch January 9, 2025

A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma

Journal of Neuro-Oncology – Irinotecan demonstrates anti-tumor efficacy in preclinical glioma models but clinical results are modest due to drug delivery limitations. Convection enhanced delivery…

Journal of Neuro-Oncology January 9, 2025

Related Articles